

**SAVE THE DATE: International Symposium
November 12 and 13, 2020
"Experimental Medicine in Lung Disease"**

Event location:

Clinical Research Center Hannover
Feodor-Lynen-Straße 15
30625 Hannover, Germany


If you have any questions, please contact Elisa Reder
elisa.reder@item.fraunhofer.de

Registration will soon be possible on this website:
<https://www.item.fraunhofer.de/20-years>



20
YEARS OF
CLINICAL RESEARCH
FRAUNHOFER ITEM





Twenty years of clinical research at Fraunhofer ITEM is a great opportunity to discuss current topics in clinical lung research with internationally renowned experts. Please **save the date** for November 12 and 13 for our symposium "Experimental Medicine in Lung Disease - 20 years Clinical Research Fraunhofer ITEM".

Prof. Dr. Norbert Krug and Prof. Dr. Jens Hohlfeld would like to welcome you with the following preliminary program:

Thursday, November 12th (afternoon)

Challenge is a challenge

Allergen Challenge Chambers – Current status, novel concepts and future needs. **Prof. Dr. Oliver Pfaar**, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Germany

Allergen-induced skin changes in the allergen challenge chamber – A model for atopic dermatitis flare-up. **Prof. Dr. Thomas Werfel**, Immunodermatology and Experimental Allergology, Hannover Medical School, Hannover, Germany

Use and predictivity of inhaled allergen challenge. **Prof. Dr. Gail Gauvreau**, Faculty of Health Sciences at McMaster University, Hamilton, Canada

Development of an inhaled GATA-3 DNase – translation from academic research into clinical development. **Prof. Dr. Harald Renz**, Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Germany

Endotoxin challenge for early phase proof-of-concept. **Prof. Dr. Jens Hohlfeld**, Fraunhofer ITEM and Hannover Medical School, Hannover, Germany

Rhinovirus challenges contributing to health and disease. **Prof. Dr. Rene Lutter**, University of Amsterdam Medical Center, Amsterdam, Netherlands

Environmental challenges – insights from the outside. **Prof. Dr. Norbert Krug**, Fraunhofer ITEM, Hannover, Germany

Harnessing environmental challenges in space. **Prof. Dr. Jens Jordan**, Institute of Aerospace Medicine, DLR, Cologne, Germany

Evening event (7pm)

Friday, November 13th (from 8:30 AM to 1:30 PM)

You can measure it, see it, get it, nebulize it

Exhaled Particle Size Index – From bench to bedside. **Dr. Katharina Schwarz**, Fraunhofer ITEM, Hannover, Germany

Multinuclear functional lung magnetic resonance imaging - seeing is believing. **Prof. Dr. Jens Vogel-Claussen**, Department of Interventional and Diagnostic Radiology, Hannover Medical School, Hannover, Germany

Facial thermography to study PK/PD relations in patients with seasonal allergic rhinitis. **Dr. Michael Larbig**, Clinical Pharmacology and Translational Development, CSL Behring, Bern, Switzerland

Sputum analysis – first generation experience and next generation chipcytometry to understand airway inflammation. **Dr. Olaf Holz**, Fraunhofer ITEM, Hannover, Germany

Blotting and Scraping the Airways: Prospect for Precision Medicine for Airways Disease. **Prof. Dr. Trevor Hansel**, Imperial Clinical Respiratory Research Unit (ICRRU), St Mary's Hospital, London, UK

Inhaled recombinant SP-C surfactant – novel device and clinical development for an old drug. **Dr. Gerhard Pohlmann**, Fraunhofer ITEM, Hannover, Germany

What did we learn about lung disease

Role of airway basal cells in chronic lung diseases. **Prof. Dr. Antje Prasse**, Clinical and Translational Fibrosis Research, Fraunhofer ITEM and Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

Data-driven phenotypes of (severe) asthma: U-BIOPRED. **Prof. Dr. Peter J. Sterk**, University of Amsterdam Medical Center, Amsterdam, Netherlands

Big data in lung research: from GWAs to systems medicine. **Prof. Dr. Thomas Illig**, Hannover Unified Biobank and Institute for Human Genetics, Hannover Medical School, Hannover, Germany

Innate lymphoid cells (ILC) 2 – Allergen-induced activation and migration to the lungs. **Dr. Carla Winkler**, Research and Early Development - Respiratory, Inflammation and Autoimmune, AstraZeneca, Mölndal, Sweden

Development of asthma treatments – past, presence and future. **Prof. Dr. Veit Erpenbeck**, Therapeutic Area Respiratory, Roche Pharma Research & Early Development, Basel, Switzerland